Integra LifeSciences (NASDAQ:IART) Issues FY25 Earnings Guidance

Integra LifeSciences (NASDAQ:IART - Get Free Report) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $2.41 to $2.51 for the period, compared to the consensus earnings per share estimate of $2.53. The company issued revenue guidance of $1.650 billion to $1.715 billion, compared to the consensus revenue estimate of $1.71 billion. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Analyst Upgrades and Downgrades

Several research firms recently commented on IART. Morgan Stanley assumed coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target on the stock. Citigroup boosted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $23.00.

Integra LifeSciences Stock Up 0.7 %

IART stock traded up $0.15 during midday trading on Friday, hitting $23.21. 698,610 shares of the company's stock were exchanged, compared to its average volume of 618,446. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -257.86, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The firm has a 50 day moving average price of $23.77 and a 200-day moving average price of $21.85. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $40.92.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm's quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.89 earnings per share. On average, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 3.10% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.